Home > Insider Trading > Filing (0000899243-22-026334)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1521036	Lantheus Holdings Inc.	LNTH	In Vitro & In Vivo Diagnostic Substances (2835)	352318913

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1876279	Andrea Sabens	C/O Lantheus Holdings, Inc. 331 Treble Cove Road North Billerica MA 01862	Chief Accounting Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2022-07-15	386	$69.12	64,255	No	4	S	Direct
Common Stock	Disposition	2022-07-18	1,093	$71.47	63,162	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	S	Direct

Footnotes

The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022.
The Form 4 originally filed on June 17, 2022 inadvertently reported 64,441 shares due to an administrative error. The correct number of shares that should have been reported under column 5 of Table I is 64,641.
The Company requires certain senior executives to cover tax liabilities resulting from the vesting of their equity awards pursuant to sell-to-cover transactions in compliance with Rule 10b5-1. This transaction reported in this Form 4 was effected in compliance with Rule 10b5-1 to satisfy withholding tax liabilities of the Reporting Person associated with the vesting of restricted stock previously granted and reported on a previously filed Form 4.